New publication 📝 Results from Part A of the phase II AMETHYST trial, presented at #EADV2026, showed sustained response with litifilimab through Week 52, with a CLA-IGA-R erythema 0/1 response rate of 27.2% in patients with CLE. Learn more about CLE: bit.ly/4B7Rh4G #Lupus #CLE #Dermatology #MedNews #MedEd

CONGRESS | #EADV2026 | PRESENTATION Victoria Werth, @Penn, presented findings from a randomized, placebo-controlled, phase II trial (NCT05591222) evaluating the efficacy and safety of daxdilimab in patients with moderate-to-severe DLE (N = 72). The primary endpoint was met, with both doses of daxdilimab significantly reducing CLASI-A scores from baseline to Week 24 compared with placebo (LS mean difference: −6.0 [90% CI, −8.7 to −3.2; p = 0.0005] for the low dose and −5.7 [90% CI, −8.5 to −2.9; p = 0.0012] for the high dose). Responses were evident as early as Week 4. Daxdilimab was well tolerated, with no cases of zoster reported. Follow our live feed for more updates: lupushub.com/medical-informa… Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #Lupus #CLE #SLE #Dermatology #MedicalCongress #MedEd #MedNews @werthlab

CONGRESS | #EADV2026 | POSTER Victoria Werth, @werthlab, @Penn, presented pooled safety data from the phase II WILLOW trial evaluating enpatoran vs PBO in patients with lupus with cutaneous manifestations, irrespective of systemic disease activity. Over 24 weeks, rates of TEAEs were 64.2% with enpatoran 25 mg (n=53), 57.8% with 50 mg (n=64) and 68.8% with 100 mg (n=80) vs 54.4% with placebo (n=68). Discontinuations due to TEAEs were low (1.9–5.0% with enpatoran vs 4.4% with placebo), and no TEAEs led to death. No new safety concerns were identified. Follow our live feed for more updates: lupushub.com/medical-informa… Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #Lupus #CLE #Dermatology #MedicalCongress #MedEd #MedNews

CONGRESS | #EADV2026 | POSTER Victoria Werth, @Penn, presented qualitative results from the phase III LAVENDER trial (NCT06015737), highlighting patient perspectives on living with CLE based on in-trial interviews (N = 26). A total of 26 different symptoms were reported by ≥2 patients; the most frequently experienced were skin redness (96%), fatigue (96%), and thickened skin/lesions (92%). A total of 23 different impacts of CLE were reported by ≥2 patients; the most frequently reported were clothing restrictions (81%), social isolation (81%), impact on leisure activities/hobbies (73%), and difficulty sleeping (73%). Follow our live feed for more updates: lupushub.com/medical-informa… Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #Lupus #CLE #SLE #Dermatology #MedicalCongress #MedEd #MedNews @werthlab

CONGRESS | #ACR25 | PRESENTATION Victoria Werth, University of Pennsylvania, discusses applying the 2025 ACR guidelines to the treatment and management of cutaneous lupus; highlighting the considerations for clinical practice using two patient case examples. Key recommendations were outlined for cutaneous lupus erythematosus (CLE), bullous LE, chilblain lupus and vasculitis. Follow our live feed for more updates: loom.ly/2QI_IUA Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #lupus #MedEd #MedicalCongress #RheumTwitter @werthlab @Penn